pentoxifylline has been researched along with Diabetes Mellitus, Type 1 in 34 studies
Diabetes Mellitus, Type 1: A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In 1985, investigators reported that four months of pentoxifylline therapy resulted in a significant decrease in proteinuria (46 percent reduction) and plasma fibrinogen concentrations (18 percent reduction) in patients with diabetes." | 7.68 | Effects of pentoxifylline on proteinuria in normotensive patients with diabetes mellitus. ( Karam, JH; Koda-Kimble, MA; White, JR, 1990) |
| "Pentoxifylline is a drug with hemorheological actions used in the management of microcirculatory abnormalities, such as those usually seen in diabetic patients." | 6.68 | Pentoxifylline reduces proteinuria in insulin-dependent and non insulin-dependent diabetic patients. ( Amato, D; García-Bulnes, G; Guerrero-Romero, F; Paniagua-Sierra, JR; Rodríguez-Morán, M; Salas-Ramírez, M, 1995) |
| "Human serum sickness is a syndrome characterized by fever, malaise, skin rashes, arthralgias, gastrointestinal disturbances, and lymphadenopathy." | 5.27 | Serum sickness associated with cefoxitin and pentoxifylline therapy. ( Gibson, K; Glynn, MJ; Hanson, VA; Panwalker, AP, 1986) |
| "Our results suggest that pentoxifylline may have a protective action for diabetic retinopathy and might modulate risk factors for atherosclerosis in type 1 diabetes." | 5.17 | Pentoxifylline treatment for protecting diabetic retinopaty in children with type 1 diabetes. ( Atabek, ME; Baykara, M; Eklioglu, BS; Kurtoglu, S, 2013) |
| "Lisofylline prevents the onset of autoimmune diabetes in NOD mice by a mechanism that does not seem to enhance the function of regulatory T cells, but could be associated with suppression of proinflammatory cytokines and reduction of cellular infiltration in islets." | 3.71 | The anti-inflammatory compound lisofylline prevents Type I diabetes in non-obese diabetic mice. ( Chen, M; McDuffie, M; Nadler, JL; Wu, R; Yang, ZD, 2002) |
| "In 1985, investigators reported that four months of pentoxifylline therapy resulted in a significant decrease in proteinuria (46 percent reduction) and plasma fibrinogen concentrations (18 percent reduction) in patients with diabetes." | 3.68 | Effects of pentoxifylline on proteinuria in normotensive patients with diabetes mellitus. ( Karam, JH; Koda-Kimble, MA; White, JR, 1990) |
| "Pentoxifylline was administered for 6 months." | 2.76 | Effectiveness of pentoxifylline on the cross-sectional area of intima media thickness and functions of the common carotid artery in adolescents with type 1 diabetes. ( Atabek, ME; Baykara, M; Kurtoglu, S; Selver, B, 2011) |
| "Pentoxifylline is a drug with hemorheological actions used in the management of microcirculatory abnormalities, such as those usually seen in diabetic patients." | 2.68 | Pentoxifylline reduces proteinuria in insulin-dependent and non insulin-dependent diabetic patients. ( Amato, D; García-Bulnes, G; Guerrero-Romero, F; Paniagua-Sierra, JR; Rodríguez-Morán, M; Salas-Ramírez, M, 1995) |
| "Lisofylline (LSF) is an anti-inflammatory molecule with high aqueous solubility and rapid metabolic interconversion to its parent drug, pentoxifylline (PTX) resulting in very poor pharmacokinetic (PK) parameters, necessitating high dose and dosing frequency." | 1.62 | Nanoparticulate tablet dosage form of lisofylline-linoleic acid conjugate for type 1 diabetes: in situ single-pass intestinal perfusion (SPIP) studies and pharmacokinetics in rat. ( Chitkara, D; Italiya, KS; Mittal, A; Singh, AK, 2021) |
| "This study demonstrates that autoimmune diabetes recurrence after islet transplantation could be prevented by treatment with LSF." | 1.32 | The novel anti-inflammatory agent lisofylline prevents autoimmune diabetic recurrence after islet transplantation. ( Carter, JD; Chen, M; Ellett, JD; Fialkow, LB; Nadler, JL; Yang, Z, 2004) |
| "Rolipram was inhibitory at concentrations as low as 10(-8) to 10(-7) mol/l, and on a molar basis, it was 100-fold more effective than PTX." | 1.30 | The phosphodiesterase inhibitors pentoxifylline and rolipram prevent diabetes in NOD mice. ( Beshay, E; Liang, L; Prud'homme, GJ, 1998) |
| "Human serum sickness is a syndrome characterized by fever, malaise, skin rashes, arthralgias, gastrointestinal disturbances, and lymphadenopathy." | 1.27 | Serum sickness associated with cefoxitin and pentoxifylline therapy. ( Gibson, K; Glynn, MJ; Hanson, VA; Panwalker, AP, 1986) |
| "Pentoxifylline was used in the treatment of 90 patients with atherosclerosis-induced chronic peripheral arterial occlusive disease and diabetic vascular disorders in the lower extremities (clinical Fontaine Stages III and IV) for whom surgical reconstructive treatment was not indicated and who had shown inadequate response to previous therapy." | 1.27 | Clinical investigation of the effects of pentoxifylline in patients with severe peripheral occlusive vascular disease. ( Seige, K; Sternitzky, R, 1985) |
| "A long-term trial with oral pentoxifylline ("Trental" 400) in a dosage of 1200 mg per day was carried out in 70 diabetic patients with and without vascular afflictions." | 1.27 | Diabetic retinal vascular complications and erythrocyte filtrability; results of a 2-year follow-up study with pentoxifylline. ( Ferrari, E; Solerte, SB, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (29.41) | 18.7374 |
| 1990's | 8 (23.53) | 18.2507 |
| 2000's | 12 (35.29) | 29.6817 |
| 2010's | 3 (8.82) | 24.3611 |
| 2020's | 1 (2.94) | 2.80 |
| Authors | Studies |
|---|---|
| Italiya, KS | 2 |
| Basak, M | 1 |
| Mazumdar, S | 1 |
| Sahel, DK | 1 |
| Shrivastava, R | 1 |
| Chitkara, D | 2 |
| Mittal, A | 2 |
| Singh, AK | 1 |
| Baykara, M | 2 |
| Atabek, ME | 2 |
| Eklioglu, BS | 1 |
| Kurtoglu, S | 2 |
| Selver, B | 1 |
| Yang, ZD | 1 |
| Chen, M | 6 |
| Wu, R | 2 |
| McDuffie, M | 1 |
| Nadler, JL | 6 |
| Yang, Z | 4 |
| Fialkow, LB | 2 |
| Ellett, JD | 2 |
| Carter, JD | 2 |
| Basaria, S | 1 |
| Braga-Basaria, M | 1 |
| Nunemaker, CS | 1 |
| Garmey, JC | 1 |
| Kimble, SD | 1 |
| Cui, P | 1 |
| Macdonald, TL | 1 |
| Valentini, M | 1 |
| Sciannameo, F | 1 |
| Francucci, M | 1 |
| Tockner, M | 1 |
| Sassano, L | 1 |
| Allegra, A | 1 |
| Pozza, G | 1 |
| Cordaro, C | 1 |
| Carandente, O | 1 |
| Margonato, A | 1 |
| Guerrero-Romero, F | 1 |
| Rodríguez-Morán, M | 1 |
| Paniagua-Sierra, JR | 1 |
| García-Bulnes, G | 1 |
| Salas-Ramírez, M | 1 |
| Amato, D | 1 |
| MacDonald, MJ | 1 |
| Shahidi, NT | 1 |
| Allen, DB | 1 |
| Lustig, RH | 1 |
| Mitchell, TL | 1 |
| Cornwell, ST | 1 |
| McDaniel, MD | 1 |
| Liang, L | 1 |
| Beshay, E | 2 |
| Prud'homme, GJ | 2 |
| Shor, NA | 1 |
| Helunenko, AM | 1 |
| Petrunia, AM | 1 |
| Zelenyĭ, II | 1 |
| Gorson, DM | 1 |
| Croze, F | 1 |
| Bello, YM | 1 |
| Phillips, TJ | 1 |
| Stosić-Grujicić, SD | 1 |
| Maksimović, DD | 1 |
| Stojković, MB | 1 |
| Lukić, ML | 2 |
| Mensah-Brown, EP | 1 |
| Stosic Grujicic, S | 1 |
| Maksimovic, D | 1 |
| Jasima, A | 1 |
| Shahin, A | 1 |
| Visser, J | 1 |
| Groen, H | 1 |
| Klatter, F | 1 |
| Rozing, J | 1 |
| Dosquet, C | 1 |
| Weill, D | 1 |
| Wautier, JL | 1 |
| White, JR | 1 |
| Karam, JH | 1 |
| Koda-Kimble, MA | 1 |
| Roul, C | 2 |
| Juhan-Vague, I | 2 |
| Rahmani-Jourdheuil, D | 2 |
| Mishal, Z | 2 |
| Vague, P | 2 |
| Mourayre, Y | 1 |
| le Petit, J | 1 |
| Ferrari, E | 2 |
| Fioravanti, M | 1 |
| Patti, AL | 1 |
| Viola, C | 1 |
| Solerte, SB | 2 |
| David, JS | 1 |
| Reichle, RM | 1 |
| Reichle, FA | 1 |
| Panwalker, AP | 1 |
| Gibson, K | 1 |
| Glynn, MJ | 1 |
| Hanson, VA | 1 |
| Utiamyshev, RI | 1 |
| Aref'ev, IM | 1 |
| Mazovetskiĭ, AG | 1 |
| Shevchenko, RA | 1 |
| Sternitzky, R | 1 |
| Seige, K | 1 |
2 reviews available for pentoxifylline and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Lisofylline: a potential lead for the treatment of diabetes.
Topics: Animals; Diabetes Mellitus, Type 1; Humans; Islets of Langerhans; Pentoxifylline | 2005 |
Molecular mechanism of blood monocyte adhesion to vascular endothelial cells.
Topics: Cell Adhesion; Cell Adhesion Molecules; Diabetes Mellitus, Type 1; Endothelium, Vascular; Humans; In | 1992 |
4 trials available for pentoxifylline and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Pentoxifylline treatment for protecting diabetic retinopaty in children with type 1 diabetes.
Topics: Adolescent; Adult; Age of Onset; Blood Flow Velocity; Carotid Artery, Common; Child; Diabetes Mellit | 2013 |
Effectiveness of pentoxifylline on the cross-sectional area of intima media thickness and functions of the common carotid artery in adolescents with type 1 diabetes.
Topics: Adolescent; Carotid Artery Diseases; Carotid Artery, Common; Carotid Intima-Media Thickness; Child; | 2011 |
[Erythrocyte filterability and treatment with pentoxifylline].
Topics: Diabetes Mellitus, Type 1; Diabetic Angiopathies; Erythrocytes; Humans; Middle Aged; Oxygen Consumpt | 1983 |
Pentoxifylline reduces proteinuria in insulin-dependent and non insulin-dependent diabetic patients.
Topics: Adult; Albuminuria; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Do | 1995 |
28 other studies available for pentoxifylline and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Scalable Self-Assembling Micellar System for Enhanced Oral Bioavailability and Efficacy of Lisofylline for Treatment of Type-I Diabetes.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Diabetes Mellitus, Type 1; Freeze Dr | 2019 |
Nanoparticulate tablet dosage form of lisofylline-linoleic acid conjugate for type 1 diabetes: in situ single-pass intestinal perfusion (SPIP) studies and pharmacokinetics in rat.
Topics: Administration, Oral; Animals; Cell Line; Cell Survival; Diabetes Mellitus, Type 1; Dosage Forms; Je | 2021 |
The anti-inflammatory compound lisofylline prevents Type I diabetes in non-obese diabetic mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Cytokines; Diabetes Mellitus, Type | 2002 |
Inhibition of STAT4 activation by lisofylline is associated with the protection of autoimmune diabetes.
Topics: Diabetes Mellitus, Type 1; DNA-Binding Proteins; Humans; Immunosuppressive Agents; Interleukin-12; P | 2003 |
The novel anti-inflammatory agent lisofylline prevents autoimmune diabetic recurrence after islet transplantation.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Cytokines; Diabetes Mellitus, Type 1; F | 2004 |
Necrobiosis lipoidica diabeticorum: response to pentoxiphylline.
Topics: Adult; Diabetes Mellitus, Type 1; Female; Hematologic Agents; Humans; Necrobiosis Lipoidica; Pentoxi | 2003 |
Combined treatment with lisofylline and exendin-4 reverses autoimmune diabetes.
Topics: Animals; Diabetes Mellitus, Type 1; Drug Combinations; Exenatide; Insulin-Secreting Cells; Mice; Mic | 2006 |
Synthesis and biological evaluation of lisofylline (LSF) analogs as a potential treatment for Type 1 diabetes.
Topics: Animals; Apoptosis; Cell Line; Chemoprevention; Cytokines; Diabetes Mellitus, Type 1; Drug Evaluatio | 2006 |
Study on relationship between erythrocyte filtration and other risk factors in diabetic angiopathy.
Topics: Diabetes Mellitus, Type 1; Diabetic Retinopathy; Erythrocytes; Female; Fibrinogen; Humans; Male; Pen | 1981 |
Pentoxifylline in the treatment of children with new-onset type I diabetes mellitus.
Topics: Adolescent; Adult; Child; Diabetes Mellitus, Type 1; Humans; Immunosuppression Therapy; Pentoxifylli | 1994 |
A 52-year-old woman with diabetes and claudication.
Topics: Coronary Disease; Decision Making; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Diabetic Nephro | 1998 |
The phosphodiesterase inhibitors pentoxifylline and rolipram prevent diabetes in NOD mice.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Antibodies, Monoclonal; CD3 Complex; Cyclic Nucleotide | 1998 |
[Disorders of the blood microcirculation in patients with suppurative-necrotic complications in diabetes mellitus and the approaches to their correction].
Topics: Adult; Aged; Chronic Disease; Combined Modality Therapy; Conjunctiva; Diabetes Mellitus, Type 1; Dia | 1998 |
Reduction of macroalbuminuria with pentoxifylline in diabetic nephropathy. Report of three cases.
Topics: Aged; Aged, 80 and over; Albuminuria; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic | 1998 |
The phosphodiesterase inhibitors pentoxifylline and rolipram suppress macrophage activation and nitric oxide production in vitro and in vivo.
Topics: 8-Bromo Cyclic Adenosine Monophosphate; Animals; Autoimmune Diseases; Bucladesine; Cells, Cultured; | 2001 |
Necrobiosis lipoidica. Indolent plaques may signal diabetes.
Topics: Adult; Diabetes Mellitus, Type 1; Diagnosis, Differential; Female; Hematologic Agents; Humans; Laser | 2001 |
Pentoxifylline prevents autoimmune mediated inflammation in low dose streptozotocin induced diabetes.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Islets of Langer | 2001 |
Downregulation of apoptosis in the target tissue prevents low-dose streptozotocin-induced autoimmune diabetes.
Topics: Animals; Apoptosis; Blood Glucose; Cell Movement; Diabetes Mellitus, Experimental; Diabetes Mellitus | 2002 |
Timing of pentoxifylline treatment determines its protective effect on diabetes development in the Bio Breeding rat.
Topics: Animals; Diabetes Mellitus, Type 1; Female; Interleukin-10; Male; Pentoxifylline; Rats; Rats, Inbred | 2002 |
Effects of pentoxifylline on proteinuria in normotensive patients with diabetes mellitus.
Topics: Adult; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Fibrino | 1990 |
[The effect of pentoxifylline and propentofylline on the membrane fluidity of red blood cells in uncontrolled insulin-dependent (type 1) diabetic patients].
Topics: Diabetes Mellitus, Type 1; Diphenylhexatriene; Erythrocyte Membrane; Fluorescence Polarization; Huma | 1988 |
Correction by pentoxifylline of the abnormal fluorescence polarization of erythrocyte membranes from diabetic patients.
Topics: Adult; Diabetes Mellitus, Type 1; Erythrocyte Membrane; Fluorescence Polarization; Humans; Middle Ag | 1987 |
Effects of long-term treatment (4 years) with pentoxifylline on haemorheological changes and vascular complications in diabetic patients.
Topics: Adult; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephrop | 1987 |
Altered low density lipoproteins in peripheral vascular disease patients.
Topics: Aged; Arterial Occlusive Diseases; Cells, Cultured; Diabetes Mellitus, Type 1; Diabetic Angiopathies | 1986 |
Serum sickness associated with cefoxitin and pentoxifylline therapy.
Topics: Cefoxitin; Diabetes Mellitus, Type 1; Drug Interactions; Humans; Male; Middle Aged; Pentoxifylline; | 1986 |
[Changes in the rate of surface blood microcirculation studied by photon-correlation spectroscopy in the practical treatment and diagnosis of diabetes mellitus].
Topics: Adolescent; Adult; Aged; Blood Flow Velocity; Conjunctiva; Diabetes Mellitus, Type 1; Diabetes Melli | 1985 |
Clinical investigation of the effects of pentoxifylline in patients with severe peripheral occlusive vascular disease.
Topics: Adult; Aged; Arterial Occlusive Diseases; Arteriosclerosis; Diabetes Mellitus, Type 1; Diabetes Mell | 1985 |
Diabetic retinal vascular complications and erythrocyte filtrability; results of a 2-year follow-up study with pentoxifylline.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopath | 1985 |